|
| Thursday, July 16, 2015 |
|
|
Uni-Bio Science Group Garners "Pharmaceuticals Award" for Best Innovation at Hong Kong Business Listed Companies Awards |
Uni-Bio Science Group Limited ("Uni-Bio" or the "Group";HKEx code: 690) has garnered the "Pharmaceuticals Award" for Best Innovation with its Uni-E4 project at the inaugural Hong Kong Business ("HKB") Listed Companies Awards. As the winner under the pharmaceuticals category, the accolade is a strong testimony for the innovation of Uni-Bio's Uni-E4, the Group's proprietary recombinant GLP-1 receptor agonist for the treatment of Type-2 diabetes.
more info >> |
|
| Saturday, May 9, 2015 |
|
|
Hong Kong Investor Relations Association Announces the Winners of its 1st IR Awards |
| Hong Kong Investor Relations Association (HKIRA) today announced the winners of its inaugural HKIRA 1st Investor Relations Awards. Guests from listed companies and the IR profession were present at today's IR Awards Conference and the Awards Presentation Ceremony to celebrate the winners' IR excellence and their dedication to IR best practice. more info >> |
|
| Thursday, May 7, 2015 |
|
|
Uni-Bio Science Group Honored at HKIRA's IR Awards |
| Uni-Bio Science Group Limited ("Uni-Bio" or the "Group";HKEx code: 690) has garnered the "Best IR Company - Small Cap" Award after passing the stringent polling process of Hong Kong Investor Relations Association's ("HKIRA") first Investor Relations Awards ("IR Awards"). more info >> |
|
| Wednesday, April 8, 2015 |
|
|
Uni-Bio Science Group's NDA for Osteoporosis Drug Uni-PTH Accepted for Review by CFDA |
| Uni-Bio Science Group Limited ("Uni-Bio" or the "Group";HKEx code: 690) today announced that its New Drug Application ("NDA") for Uni-PTH, the Group's proprietary parathyroid hormone 1-34 analogue more info >> |
|
| Saturday, March 28, 2015 |
|
|
Uni-Bio Science Group Announces Final Results |
| Uni-Bio Science Group Limited ("Uni-Bio" or the "Group;" HKEx code: 0690) has announced its results for the nine months ended 31 December 2014 (the "Period"), subsequent to its announcement of changing the end date for its financial year from 31 March to 31 December earlier in 2014. more info >> |
|
| Wednesday, November 26, 2014 |
|
|
Uni-Bio Science Group Announces 2014/15 Interim Results |
Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group"; HKEx code: 690) has announced its interim results for the six months ended 30 September 2014. Backed by a strong management team and guided by a clear development roadmap, the Group achieved solid growth as it continued to expand its core business and strengthened its business foundation through various initiatives during the period under review.
more info >> |
|
| Monday, September 1, 2014 |
|
|
Uni-Bio Science Group Forms Strategic Alliance with Korean Pharmaceutical Company Samil |
| Uni-Bio Science Group Limited ("Uni-Bio" or the "Group;" HKEx code: 690) today announced that it has entered into a strategic alliance agreement with Samil Pharm Co., Limited more info >> |
|
| Monday, June 30, 2014 |
|
|
Uni-Bio Science Group 2013/14 Annual Turnover Beats Industry Growth |
Uni-Bio Science Group Limited ("Uni-Bio" or the "Group;" HKEx code: 690) has achieved an outstanding performance during the financial year 2013/14. The Group's topline growth beat the industry average while its two new prescription drugs, Uni-E4 and Uni-PTH, both reached major clinical milestone of completing all required clinical trials.
more info >> |
|
|
Uni-Bio Science Group's Osteoporosis Drug Uni-PTH Meets Phase III Primary Endpoint |
Uni-Bio Science Group Limited ("Uni-Bio" or the "Group;" HKEx code: 690) today reports successful Phase III clinical trial results of Uni-PTH, a once-daily prescription new drug for osteoporosis.
more info >> |
|
| Tuesday, April 1, 2014 |
|
|
Uni-Bio Science Group Bolsters Top Management and Board with Industry Veterans |
| Uni-Bio Science Group Limited ("Uni-Bio" or the "Group") (SEHK code: 690) strengthened the composition of the Board of Directors ("Board") and senior management team to enhance business fundamentals and to initiate new business development strategies. more info >> |
|
|
|
